Given these compelling results, Creative Medical Technology plans to advance the development of AlloStem (CELZ-201) for the treatment of late-stage Type 2 Diabetes and explore other potential ...
Citi analyst Filippo Falorni maintained a Buy rating and an $85.00 price target for Coca-Cola (NYSE:KO) stock. According to ...
Truist Securities adjusted its price target for Inspire Medical Systems (NYSE:INSP) stock, lowering it from $250.00 to $235.00 while maintaining a Buy rating. The adjustment follows the company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback